New Biotage Facility Tackles mRNA Vaccine Bottleneck
Biotage (Uppsala, Sweden) has announced an expansion of its production capacity of large-scale flash columns by 300% at a new production facility in Cardiff, UK. The expansion will allow Biotage to help pharmaceutical companies and contract manufacturers to scale-up lipid production for COVID-19 vaccines.
“Our customers needed to manufacture their products on a significantly larger scale, and we were able to invest in an expansion of our existing production facilities to support their requirements. We were very pleased to be able to deliver this expansion in just over four months in order to meet the needs of present and potential new clients,” said Anders Wikström, EVP Operations of Biotage.
The availability of raw materials for mRNA vaccine production has been a major bottleneck as the lipids that were needed for new lipid nanoparticle (LNP) formulations, which are used in mRNA vaccines, were not previously available on the scale needed to produce billions of doses of vaccine globally.
The newly opened production facility will enable Biotage to meet the increase in demand for this vital market segment.
For more information, please visit: www.biotage.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
